PGEN
Price
$4.78
Change
+$0.27 (+5.99%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
1.34B
71 days until earnings call
XENE
Price
$39.30
Change
+$0.59 (+1.52%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
2.98B
64 days until earnings call
Interact to see
Advertisement

PGEN vs XENE

Header iconPGEN vs XENE Comparison
Open Charts PGEN vs XENEBanner chart's image
Precigen
Price$4.78
Change+$0.27 (+5.99%)
Volume$303.45K
Capitalization1.34B
Xenon Pharmaceuticals
Price$39.30
Change+$0.59 (+1.52%)
Volume$9.59K
Capitalization2.98B
PGEN vs XENE Comparison Chart in %
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. XENE commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a StrongBuy and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (PGEN: $4.51 vs. XENE: $38.71)
Brand notoriety: PGEN and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 101% vs. XENE: 59%
Market capitalization -- PGEN: $1.34B vs. XENE: $2.98B
PGEN [@Biotechnology] is valued at $1.34B. XENE’s [@Biotechnology] market capitalization is $2.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • PGEN’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than PGEN.

Price Growth

PGEN (@Biotechnology) experienced а +7.89% price change this week, while XENE (@Biotechnology) price change was -0.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

PGEN is expected to report earnings on Nov 12, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.99B) has a higher market cap than PGEN($1.34B). PGEN YTD gains are higher at: 302.679 vs. XENE (-1.250). PGEN has higher annual earnings (EBITDA): -121.98M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. PGEN (59.8M). PGEN has less debt than XENE: PGEN (5.15M) vs XENE (8.72M). XENE has higher revenues than PGEN: XENE (7.5M) vs PGEN (4.34M).
PGENXENEPGEN / XENE
Capitalization1.34B2.99B45%
EBITDA-121.98M-315.5M39%
Gain YTD302.679-1.250-24,214%
P/E RatioN/AN/A-
Revenue4.34M7.5M58%
Total Cash59.8M488M12%
Total Debt5.15M8.72M59%
FUNDAMENTALS RATINGS
PGEN vs XENE: Fundamental Ratings
PGEN
XENE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
9837
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3442
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
9045

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (73) in the null industry is in the same range as XENE (75) in the Biotechnology industry. This means that PGEN’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (37) in the Biotechnology industry is somewhat better than the same rating for PGEN (98) in the null industry. This means that XENE’s stock grew somewhat faster than PGEN’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that XENE’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (34) in the null industry is in the same range as XENE (42) in the Biotechnology industry. This means that PGEN’s stock grew similarly to XENE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that XENE’s stock grew significantly faster than PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENXENE
RSI
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 5 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
74%
Momentum
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
77%
MACD
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
86%
Bearish Trend 5 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
86%
Bullish Trend 5 days ago
74%
Advances
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 15 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
78%
Aroon
ODDS (%)
Bullish Trend 5 days ago
88%
Bullish Trend 5 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSVSX16.17-0.05
-0.31%
Janus Henderson Small-Mid Cap Value S
GBLCX40.37-0.13
-0.32%
American Funds Global Balanced C
SRVEX24.64-0.22
-0.88%
Victory Diversified Stock A
GGOSX10.78-0.11
-1.01%
Goldman Sachs Mid Cap Growth Svc
JGSVX22.33-0.28
-1.24%
JPMorgan Small Cap Growth R5

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-0.88%
XENE - PGEN
39%
Loosely correlated
+0.28%
ZNTL - PGEN
38%
Loosely correlated
-3.98%
KPTI - PGEN
38%
Loosely correlated
-7.42%
MGNX - PGEN
38%
Loosely correlated
+4.12%
IMNM - PGEN
38%
Loosely correlated
-3.94%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.28%
IDYA - XENE
58%
Loosely correlated
-1.52%
CRNX - XENE
55%
Loosely correlated
+1.11%
NRIX - XENE
51%
Loosely correlated
-0.74%
ATXS - XENE
51%
Loosely correlated
-5.36%
ADVM - XENE
51%
Loosely correlated
+1.65%
More